Sci Rep:一种新型简单的干眼症筛查方法-很大眨眼间隔

2018-09-20 MedSci MedSci原创

日本东京眼科的Inomata T等人近日在Sci Rep发表了他们实验团队一项成果。目前,干眼病(DED)的患病率在世界范围内呈现增加趋势,其诊断通常需要专用的试剂和机器。他们在筛查DED时,研究了最大眨眼间隔(MBI)(参与者可以睁开眼睛的时间长短)是否可以作为诊断疾病的指标。

日本东京眼科的Inomata T等人近日在Sci Rep发表了他们实验团队一项成果。目前,干眼病(DED)的患病率在世界范围内呈现增加趋势,其诊断通常需要专用的试剂和机器。他们在筛查DED时,研究了最大眨眼间隔(MBI)(参与者可以睁开眼睛的时间长短)是否可以作为诊断疾病的指标。

这是一项横断面研究,研究群体包括2016年9月至2017年9月期间招募的292名患者(194名患有DED,98名未患DED)。他们比较了是否患有DED患者之间的MBI,研究MBI与DED其他临床特征之间的相关性,主要包括主观症状(干眼相关的生活质量评分)、泪膜破裂时间(TFBUT)、角膜荧光评分(CFS)和Schirmer试验I值等。同时,使用ROC分析确定MBI的最佳截止值。

结果发现,与非DED组相比,DED组的MBI显着缩短(10.0±9.1对24.3±38.2秒,p <0.001)。 TFBUT与MBI呈显着的正相关(r = 0.464),而CFS与MBI呈负相关(r = -0.273)。 ROC曲线下面积为0.677,最佳MBI截止值为12.4秒,对可能是DED患者的敏感性为82.5%,特异性为51.0%。

总之,MBI可能是筛选DED的简单有用的指标。

原文出处:

Inomata, T., et al., Maximum blink interval is associated with tear film breakup time: A new simple, screening test for dry eye disease. Sci Rep, 2018. 8(1): p. 13443.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745780, encodeId=635f1e457809f, content=<a href='/topic/show?id=e46ce2690c5' target=_blank style='color:#2F92EE;'>#眨眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72690, encryptionId=e46ce2690c5, topicName=眨眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4db35575993, createdName=zz82, createdTime=Wed Jul 24 09:23:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042430, encodeId=a6682042430ca, content=<a href='/topic/show?id=9f0ae59339a' target=_blank style='color:#2F92EE;'>#筛查方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75933, encryptionId=9f0ae59339a, topicName=筛查方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Dec 08 20:23:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376847, encodeId=106f13e6847c5, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527323, encodeId=2ae3152e323f0, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2019-07-24 zz82
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745780, encodeId=635f1e457809f, content=<a href='/topic/show?id=e46ce2690c5' target=_blank style='color:#2F92EE;'>#眨眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72690, encryptionId=e46ce2690c5, topicName=眨眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4db35575993, createdName=zz82, createdTime=Wed Jul 24 09:23:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042430, encodeId=a6682042430ca, content=<a href='/topic/show?id=9f0ae59339a' target=_blank style='color:#2F92EE;'>#筛查方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75933, encryptionId=9f0ae59339a, topicName=筛查方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Dec 08 20:23:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376847, encodeId=106f13e6847c5, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527323, encodeId=2ae3152e323f0, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745780, encodeId=635f1e457809f, content=<a href='/topic/show?id=e46ce2690c5' target=_blank style='color:#2F92EE;'>#眨眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72690, encryptionId=e46ce2690c5, topicName=眨眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4db35575993, createdName=zz82, createdTime=Wed Jul 24 09:23:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042430, encodeId=a6682042430ca, content=<a href='/topic/show?id=9f0ae59339a' target=_blank style='color:#2F92EE;'>#筛查方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75933, encryptionId=9f0ae59339a, topicName=筛查方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Dec 08 20:23:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376847, encodeId=106f13e6847c5, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527323, encodeId=2ae3152e323f0, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2018-09-22 yeaweam
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745780, encodeId=635f1e457809f, content=<a href='/topic/show?id=e46ce2690c5' target=_blank style='color:#2F92EE;'>#眨眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72690, encryptionId=e46ce2690c5, topicName=眨眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4db35575993, createdName=zz82, createdTime=Wed Jul 24 09:23:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042430, encodeId=a6682042430ca, content=<a href='/topic/show?id=9f0ae59339a' target=_blank style='color:#2F92EE;'>#筛查方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75933, encryptionId=9f0ae59339a, topicName=筛查方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Dec 08 20:23:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376847, encodeId=106f13e6847c5, content=<a href='/topic/show?id=391248e4933' target=_blank style='color:#2F92EE;'>#干眼症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48749, encryptionId=391248e4933, topicName=干眼症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527323, encodeId=2ae3152e323f0, content=<a href='/topic/show?id=533248e474a' target=_blank style='color:#2F92EE;'>#干眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48747, encryptionId=533248e474a, topicName=干眼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11b211837688, createdName=nian.wang1986, createdTime=Sat Sep 22 12:23:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]

相关资讯

鱼油治疗干眼症大型临床试验失败

知名相声演员岳云鹏(小岳岳),曾发微博倾诉和求助:他饱受着严重干眼症的痛苦折磨,试过多种治疗都见效甚微。小岳岳表示,谁治好他的干眼症就以身相许!干眼症是临床上较常见的一种眼部疾病——眼部角结膜干燥症。干眼症是由于眼结膜组织病变引发炎症,出现泪液分泌量减少、泪液成分改变、结膜松弛引起泪膜不稳定,患者会出现各种眼部不适症状,严重时甚至影响视觉功能,造成日常工作和生活困扰。现有的治疗,对绝大多数患者而言

干眼症知多少

复旦大学附属眼耳鼻喉科医院药剂科 沈剑文 干眼症又称结膜干燥症,是很常见的眼表疾病。是指各种原因引起的泪液质和量或动力学异常,导致泪膜不稳定和眼表组织的病变,并伴有眼部不适症状为特征的一类疾病的总称。

Ocul Surf:短时间泪膜破裂的干眼症患者的角膜触觉和疼痛感研究

日本北海道大学医学部和医学研究科眼科的Tagawa Y等人近日在Ocul Surf杂志发表一项重要工作,他们评估了短时间泪膜破裂干眼症(sBUT DE)患者的角膜触觉和疼痛感。

NEJM:鱼油对干眼症无明显治疗效果

现代人使用手机、电脑过度,极易引发干眼症等眼部不适。通常人们认为,鱼油中富含欧米茄-3脂肪酸,对干眼症有一定的辅助治疗作用。然而,美国一项最新研究结果推翻了这一认知。

N Engl J Med:缓解干眼症 鱼油遭打脸

干眼症是临床上较常见的一种眼部疾病,患者会出现各种眼部不适症状,严重时甚至影响视觉功能。发表在《N Engl J Med》的一项多中心、双盲临床研究调查了n?3脂肪酸补充剂(通常叫做ω-3脂肪酸)治疗干眼症的疗效。

Contemp Clin Trials:干眼症诊断和治疗(DREAM)研究

美国纽约伊坎医学院眼科系的Asbell PA近日在Contemp Clin Trials发表了一篇文章,描述了DRy眼睛诊断和治疗(DREAM)研究参与者对试验设计等基本特征。